On Monday, Following U.S. Stocks were among the “Top Losers”: Synthetic Biologics Inc (NYSEMKT:SYN), Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Natural Resource PartnersLP (NYSE:NRP), Second Sight Medical Products, Inc. (NASDAQ:EYES)

Latest NEWS regarding these Stocks are depicted underneath:

Synthetic Biologics Inc. (NYSEMKT:SYN)

Synthetic Biologics Inc. (SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, stated financial results for the year ended December 31, 2014, and offered an operational update.

Clinical Programs Update:

SYN-004 is a first-in-class oral enzyme preventive therapy designed to protect the gut microbiome from the unintended harmful effects of intravenous (IV) antibiotics, for the prevention of C. difficile infection.

• Established Clinical Advisory Board and strengthened intellectual property portfolio
• Accomplished Phase 1a and 1b clinical trials; stated positive topline safety and tolerability data from both studies
• Plan to initiate a Phase 2a clinical trial to evaluate gastrointestinal (GI) antibiotic-degrading effects and safety (1Q 2015); expect topline data (1H 2015)
• Presenting poster of late-breaking preclinical data for protection of microbiome at Digestive Disease Week® (May 2015)
• Plan to initiate a Phase 2b proof-of-concept clinical trial (2H 2015); expect topline data (2H 2015).

SYN-010 is a proprietary, modified-release statin formulation optimal for reducing methane-production by certain microorganisms in the gut to treat the underlying cause of pain, bloating, and constipation associated with IBS-C.

• Established Clinical Advisory Board and strengthened intellectual property portfolio
• A 505(b)(2) regulatory pathway is anticipated for development
• Poster presentation of preclinical data by lead principal investigator of Cedars-Sinai Medical Center at Digestive Disease Week® (May 2015)
• Expect to submit an Investigational New Drug (IND) application to initiate clinical trials (1H 2015)
• Plan to initiate Phase 2 clinical trials (2Q 2015); expect topline data (2H 2015)

SYN-005 is a novel combination of two monoclonal antibodies designed to treat Pertussis (whooping cough) by targeting and neutralizing pertussis toxin.

• Strengthened intellectual property portfolio
• Stated positive preclinical research findings from non-human primate studies
• Granted U.S. Orphan Drug designation by the FDA
• Seeking non-dilutive funding to support clinical development (ongoing)

TrimestaTM (oral estriol) may offer a differentiated mechanism of action in the treatment of RRMS, as demonstrated in clinical trials. Based on Phase 2 clinical findings, Trimesta may offer both anti-inflammatory (decrease in relapse rate) and neuroprotective (improvements in disability and cognition) benefits for patients with MS when taken in combination with Copaxone®.

• Expanded efficacy and safety results from the investigator-initiated Phase 2 trial evaluating adjunctive Trimesta in women with RRMS counting positive results on cognitive and disability scores at 12 months, attesting to Trimesta’s unique neuroprotective properties, were presented at the ACTRIMS-ECTRIMS meeting in Boston in September 2014 by the trial’s lead investigator.
• Strengthened intellectual property portfolio
• As formerly revealed, active talk aboutions with a number of potential planned partners may accelerate development of Trimesta (ongoing)
• MRI brain scan analyses underway to evaluate changes in the brain that correlate with improvements seen in clinical outcomes; topline data predictable from the principal investigator during the first half of 2015
• A separate multi-center U.S. Phase 2 trial is underway focused exclusively on cognition utilizing Trimesta with a variety of presently marketed MS drugs, counting Copaxone®, Avonex®, Betaseron®, Extavia®, Rebif®, Gilenya®, Aubagio® and Tecfidera®

Synthetics Biologics, Inc., a biotechnology corporation, focuses on development of novel anti-infective biologics and drug candidates targeting specific pathogens that cause serious infections and other diseases.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

Progenics Pharmaceuticals, Inc. (PGNX), declared its results of operations for the fourth quarter and year-end 2014. Net loss for the quarter was $12.2 million or $0.18 diluted per share, contrast to net loss of $8.6 million or $0.14 diluted per share in the 2013 period. Net revenue for the year-end 2014 was $4.4 million or $0.06 diluted per share, contrast to net loss of $42.6 million or $0.76 diluted per share in 2013.

Progenics ended the year with cash and cash equivalents of $119.3 million, reflecting raises of $34.1 million in the quarter and $53.4 million from 2013 year-end, resulting primarily from $40.0 million milestone payment received in October for the expanded approval of RELISTOR(R) Subcutaneous Injection for patients with non-cancer pain, the third quarter receipt of $7.25 million upon settlement of an arbitration with its former RELISTOR licensee for Japan and a first quarter financing of $37.5 million.

Fourth quarter proceed resulted in a loss of $0.6 million, primarily from RELISTOR royalty losses due to Salix’s plan to accelerate the reduction of wholesaler inventory levels and substantially cease all sales efforts to wholesalers in the fourth quarter of 2014. This compares to proceeds of $3.0 million due to RELISTOR royalty revenue in the fourth quarter of 2013.

Full year 2014 proceed was $44.4 million, up from $7.9 million in the preceding year, reflecting an raise in partnership proceed of $39.6 million, primarily resulting from the recognition of the $40.0 million milestone from Salix, partially offset by a $2.8 million decrease in RELISTOR royalty revenue to $3.1 million, contrast to $5.9 million in 2013.

Fourth quarter research and development expenses reduced by $1.5 million contrast to the preceding year period, reflecting lower clinical trial expenses for MIP-1404 and PSMA ADC, and lower compensation expenses, partially offset by higher contract manufacturing expenses for AZEDRA, MIP-1404, and PSMA ADC and clinical trial expenses for Azedra. The full year research and development expenses reduced by $6.0 million contrast to the preceding year period. Fourth quarter general and administrative expenses raised $0.5 million, contrast to the preceding year period, primarily due to higher legal expenses. The full year general and administrative expenses raised $0.3 million from the preceding period. Non-cash items for the quarter and year resulted from impairment charges and raised estimates for fair value of contingent consideration liability related to the 2013 attainment of Molecular Insight.

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that comprises several product candidates in later-stage clinical development. Progenics’ first-in-class PSMA-targeted technology platform for prostate cancer comprises an antibody drug conjugate therapeutic which accomplished a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also accomplished a phase 2 trial.

Natural Resource Partners LP (NYSE:NRP)

Formerly on February 27, Natural Resource Partners LP (NRP), declared that it has filed its Form 10-K for the period ended December 31, 2014 with the Securities and Exchange Commission. The report is accessible for viewing or downloading on its website www.nrplp.com. Unitholders may request a hardcopy of the complete audited financial statements, free of charge, at [email protected] or by contacting the partnership at 601 Jefferson, Suite 3600, Houston, TX 77002.

NRP has also accomplished the mailing of its 2014 tax packages for unitholders, counting the individual K-1 tax information. The K-1 tax information may also be accessed online, by registering on NRP’s website at www.nrplp.com/taxpackagesupport.

Natural Resource Partners L.P. is a master limited partnership headquartered in Houston, TX. NRP is a diversified natural resource corporation that owns interests in oil and gas, coal, aggregates and industrial minerals across the United States. A large percentage of NRP’s proceeds are generated from royalties and other passive revenue.

Second Sight Medical Products, Inc. (NASDAQ:EYES)

During the month of February, Second Sight Medical Products, Inc. (EYES), were the beneficiary of a noteworthy raise in short interest. As of February 27th, there was short interest totaling 1,247,175 shares, a lift of 42.4% from the February 13th total of 875,914 shares, American Banking News reports. Right now, 8.7% of the shares of the corporation are sold short. Based on an average daily trading volume, of 3,551,184 shares, the short-interest ratio is presently 0.4 days.

Second Sight Medical Products, Inc., a medical device corporation, develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.